Wall Street Trader schreef op 28 januari 2021 10:52:
Gilead and Galapagos have framed safety as a positive differentiator for filgotinib/Jyseleca over other JAK1 inhibitors, which so far have all come with a black box warning. However, the effect of the drug on sperm is a long-standing concern.
Abrahams detailed in a note to clients that Pfizer's results could weigh on an experimental drug from the Belgian biotech company Galapagos, as well as Incyte, which is working to get a topical version of its JAK drug Jakafi approved.
At the same time, the results could open the door for non-JAK programs in development at Galapagos and Gilead, Abrahams argues.
Comparison of Black Box Warnings